X |
Filing Date |
Trade Date |
Ticker |
Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-04-25 | GLSI | Patel Snehal | CEO, CFO, 10% | P - Purchase | $9.88 | +3,600 | 5,570,602 | 0% | +$35,568 | ||||||
2025-04-17 | GLSI | Patel Snehal | CEO, CFO, 10% | P - Purchase | $8.98 | +5,400 | 5,567,002 | 0% | +$48,492 | ||||||
2025-04-07 | GLSI | Patel Snehal | CEO, CFO, 10% | P - Purchase | $9.10 | +3,600 | 5,561,602 | 0% | +$32,760 | ||||||
2025-04-04 | GLSI | Patel Snehal | CEO, CFO, 10% | P - Purchase | $8.73 | +5,500 | 5,558,002 | 0% | +$48,015 | ||||||
2025-01-10 | GLSI | Patel Snehal | CEO, CFO, 10% | P - Purchase | $12.51 | +2,500 | 5,552,502 | 0% | +$31,275 | ||||||
| M | 2025-01-06 | GLSI | Patel Snehal | CEO, CFO, 10% | P - Purchase | $13.58 | +2,900 | 5,550,002 | 0% | +$39,391 | |||||
2025-01-03 | GLSI | Patel Snehal | CEO, CFO, 10% | P - Purchase | $12.95 | +3,400 | 5,547,102 | 0% | +$44,030 | ||||||
2025-01-02 | GLSI | Patel Snehal | CEO, CFO, 10% | P - Purchase | $11.97 | +2,000 | 5,543,702 | 0% | +$23,940 | ||||||
2024-12-31 | GLSI | Patel Snehal | CEO, CFO, 10% | P - Purchase | $11.36 | +2,400 | 5,541,702 | 0% | +$27,264 | ||||||
2024-12-30 | GLSI | Patel Snehal | CEO, CFO, 10% | P - Purchase | $11.12 | +3,200 | 5,539,302 | 0% | +$35,584 | ||||||
2024-11-21 | GLSI | Thompson Jaye | VP Clinical Reg Affairs | P - Purchase | $12.91 | +1,000 | 264,148 | 0% | +$12,910 | ||||||
2024-09-26 | GLSI | Patel Snehal | CEO, CFO, 10% | P - Purchase | $14.63 | +1,500 | 5,536,102 | 0% | +$21,945 | ||||||
2024-08-12 | GLSI | Thompson Jaye | VP Clinical Reg Affairs | P - Purchase | $13.85 | +800 | 263,148 | 0% | +$11,080 | ||||||
2024-08-06 | GLSI | Patel Snehal | CEO, CFO, 10% | P - Purchase | $13.81 | +2,000 | 5,534,602 | 0% | +$27,620 | ||||||
2024-08-05 | GLSI | Patel Snehal | CEO, CFO, 10% | P - Purchase | $13.18 | +5,500 | 5,532,602 | 0% | +$72,490 | ||||||
2024-08-02 | GLSI | Thompson Jaye | VP Clinical Reg Affairs | P - Purchase | $15.15 | +1,000 | 262,348 | 0% | +$15,150 | ||||||
2024-07-23 | GLSI | Patel Snehal | CEO, CFO, 10% | P - Purchase | $15.89 | +1,500 | 5,527,102 | 0% | +$23,835 | ||||||
2024-07-18 | GLSI | Thompson Jaye | VP Clinical Reg Affairs | P - Purchase | $16.00 | +1,000 | 261,348 | 0% | +$16,000 | ||||||
2024-06-13 | GLSI | Patel Snehal | CEO, CFO, 10% | P - Purchase | $14.30 | +174,825 | 5,525,602 | +3% | +$2,499,998 | ||||||
2024-04-01 | GLSI | Patel Snehal | CEO, CFO, 10% | P - Purchase | $19.08 | +3,000 | 5,350,777 | 0% | +$57,240 | ||||||
2024-03-22 | GLSI | Patel Snehal | CEO, CFO, 10% | P - Purchase | $19.98 | +2,500 | 5,347,777 | 0% | +$49,950 | ||||||
2024-03-20 | GLSI | Patel Snehal | CEO, CFO, 10% | P - Purchase | $17.68 | +1,500 | 5,345,277 | 0% | +$26,520 | ||||||
| A | 2024-03-05 | GLSI | Patel Snehal | CEO, CFO, 10% | P - Purchase | $12.49 | +3,500 | 5,343,777 | 0% | +$43,715 | |||||
2024-03-05 | GLSI | Patel Snehal | CEO, CFO, 10% | P - Purchase | $12.49 | +30,500 | 5,343,777 | +1% | +$380,945 | ||||||
2024-03-04 | GLSI | Patel Snehal | CEO, CFO, 10% | P - Purchase | $13.03 | +4,100 | 5,340,277 | 0% | +$53,423 | ||||||
2024-02-16 | GLSI | Patel Snehal | CEO, CFO, 10% | P - Purchase | $11.16 | +10,800 | 5,336,177 | 0% | +$120,528 | ||||||
2024-02-15 | GLSI | Patel Snehal | CEO, CFO, 10% | P - Purchase | $11.07 | +12,700 | 5,325,377 | 0% | +$140,589 | ||||||
2023-11-10 | GLSI | Patel Snehal | CEO, CFO, 10% | P - Purchase | $10.17 | +5,000 | 5,312,677 | 0% | +$50,838 | ||||||
2023-11-03 | GLSI | Patel Snehal | CEO, CFO, 10% | P - Purchase | $9.11 | +3,500 | 5,307,677 | 0% | +$31,885 | ||||||
2023-10-27 | GLSI | Thompson Jaye | VP Clinical Reg Affairs | P - Purchase | $8.57 | +500 | 260,348 | 0% | +$4,285 | ||||||
2023-10-26 | GLSI | Patel Snehal | CEO, CFO, 10% | P - Purchase | $7.97 | +2,500 | 5,304,177 | 0% | +$19,925 | ||||||
2023-10-25 | GLSI | Patel Snehal | CEO, CFO, 10% | P - Purchase | $7.91 | +2,500 | 5,301,677 | 0% | +$19,775 | ||||||
2023-10-10 | GLSI | Patel Snehal | CEO, CFO, 10% | P - Purchase | $9.07 | +1,000 | 5,299,177 | 0% | +$9,070 | ||||||
2023-10-04 | GLSI | Patel Snehal | CEO, CFO, 10% | P - Purchase | $8.63 | +2,000 | 5,298,177 | 0% | +$17,260 | ||||||
2023-09-26 | GLSI | Thompson Jaye | VP Clinical Reg Affairs | P - Purchase | $8.71 | +600 | 259,848 | 0% | +$5,226 | ||||||
2023-09-19 | GLSI | Patel Snehal | CEO, CFO, 10% | P - Purchase | $8.95 | +4,000 | 5,296,177 | 0% | +$35,800 | ||||||
2023-09-11 | GLSI | Patel Snehal | CEO, CFO, 10% | P - Purchase | $9.48 | +1,000 | 5,292,177 | 0% | +$9,480 | ||||||
2023-08-22 | GLSI | Patel Snehal | CEO, CFO, 10% | P - Purchase | $9.97 | +1,000 | 5,291,177 | 0% | +$9,970 | ||||||
2023-08-04 | GLSI | Patel Snehal | CEO, CFO, 10% | P - Purchase | $10.55 | +2,000 | 5,290,177 | 0% | +$21,100 | ||||||
2023-07-21 | GLSI | Patel Snehal | CEO, CFO, 10% | P - Purchase | $9.20 | +1,000 | 5,288,177 | 0% | +$9,200 | ||||||
2023-07-13 | GLSI | Thompson Jaye | VP Clinical Reg Affairs | P - Purchase | $9.49 | +250 | 259,248 | 0% | +$2,373 | ||||||
2023-05-17 | GLSI | Patel Snehal | CEO, CFO, 10% | P - Purchase | $11.69 | +1,000 | 5,287,177 | 0% | +$11,690 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |